Aphria Inc. produces and sells medical cannabis in Canada and internationally.
Reasonable growth potential and fair value.
Share Price & News
How has Aphria's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APHA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: APHA exceeded the Canadian Pharmaceuticals industry which returned -73.5% over the past year.
Return vs Market: APHA underperformed the Canadian Market which returned -26% over the past year.
Price Volatility Vs. Market
How volatile is Aphria's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StHave Insiders Been Selling Aphria Inc (TSE:APHA) Shares?
1 year ago | Simply Wall StWhat You Must Know About Aphria Inc's (TSE:APHA) Financial Health
1 year ago | Simply Wall StWhy Aphria Inc's (TSE:APHA) High P/E Ratio Isn't Necessarily A Bad Thing
Is Aphria undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APHA (CA$4.65) is trading below our estimate of fair value (CA$18.95)
Significantly Below Fair Value: APHA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APHA is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: APHA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APHA is good value based on its PB Ratio (0.7x) compared to the CA Pharmaceuticals industry average (0.9x).
How is Aphria forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APHA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: APHA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: APHA's is expected to become profitable in the next 3 years.
Revenue vs Market: APHA's revenue (17.6% per year) is forecast to grow faster than the Canadian market (3.9% per year).
High Growth Revenue: APHA's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APHA's Return on Equity is forecast to be low in 3 years time (2.9%).
How has Aphria performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APHA is currently unprofitable.
Growing Profit Margin: APHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APHA is unprofitable, and losses have increased over the past 5 years at a rate of -6.6% per year.
Accelerating Growth: Unable to compare APHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-9.9%).
Return on Equity
High ROE: APHA has a negative Return on Equity (-4.78%), as it is currently unprofitable.
How is Aphria's financial position?
Financial Position Analysis
Short Term Liabilities: APHA's short term assets (CA$828.4M) exceed its short term liabilities (CA$152.5M).
Long Term Liabilities: APHA's short term assets (CA$828.4M) exceed its long term liabilities (CA$581.2M).
Debt to Equity History and Analysis
Debt Level: APHA's debt to equity ratio (28.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if APHA's debt to equity ratio has reduced over the past 5 years.
Inventory Level: APHA has a high level of physical assets or inventory.
Debt Coverage by Assets: APHA's debt is covered by short term assets (assets are 1.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APHA has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: APHA has been profitable on average in the past, therefore cash runway is not a concern.
What is Aphria's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate APHA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APHA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APHA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Irwin Simon (60yo)
Mr. Irwin D. Simon has been an Chairman of Aphria Inc. since December 27, 2018 and serves as its Chief Executive Officer since February 2020 and served as its Interim Chief Executive Officer from March 01, ...
CEO Compensation Analysis
Compensation vs Market: Irwin's total compensation ($USD6.81M) is above average for companies of similar size in the Canadian market ($USD1.69M).
Compensation vs Earnings: Insufficient data to compare Irwin's compensation with company performance.
|CEO & Chairman||1yr||CA$9.58m||no data|
|Chief Financial Officer||4.25yrs||CA$1.37m||0.037% CA$423.4k|
|Chief Legal Officer||1.67yrs||CA$1.61m||0.017% CA$194.9k|
|Special Advisor||1yr||CA$1.00m||no data|
|Special Advisor||1yr||CA$457.89k||no data|
|Managing Director of Aphria Germany||no data||CA$691.96k||no data|
|Chief Operating Officer of Aphria Leamington||0.83yr||no data||no data|
|Chief Science Officer||no data||no data||0.067% CA$780.0k|
|Vice President of Investor Relations||1.42yrs||no data||no data|
|Chief Marketing Officer||no data||CA$942.04k||0.0071% CA$82.3k|
Experienced Management: APHA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
|CEO & Chairman||1yr||CA$9.58m||no data|
|Independent Director||0.83yr||CA$33.17k||0.0019% CA$21.6k|
|Independent Director||0.83yr||CA$33.17k||no data|
|Lead Independent Director||1.25yrs||CA$332.96k||no data|
|Independent Director||1.25yrs||CA$256.28k||0.00028% CA$3.2k|
|Independent Director||0.25yr||no data||no data|
|Vice Chairman of the Board & Lead Director||0.17yr||CA$423.88k||0.0070% CA$80.8k|
Experienced Board: APHA's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: APHA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.
Aphria Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aphria Inc.
- Ticker: APHA
- Exchange: TSX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.157b
- Shares outstanding: 267.25m
- Website: https://aphriainc.com
Number of Employees
- Aphria Inc.
- 245 Talbot Street West
- Suite 103
- N8H 3C4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|APHA||TSX (The Toronto Stock Exchange)||Yes||Common Shares||CA||CAD||Dec 2014|
|APHA||NYSE (New York Stock Exchange)||Yes||Common Shares||US||USD||Dec 2014|
|10E||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Dec 2014|
|0UI4||LSE (London Stock Exchange)||Yes||Common Shares||GB||CAD||Dec 2014|
Aphria Inc. produces and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis; and adult-use cannabis under the Solei, RIFF, Good Supply, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 03:30|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.